دورية أكاديمية
أعرض في EDS

The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.

التفاصيل البيبلوغرافية
العنوان: The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.
المؤلفون: Cruickshank M; Health Services Research Unit, University of Aberdeen, Aberdeen, UK., Hudson J; Health Services Research Unit, University of Aberdeen, Aberdeen, UK., Hernández R; Health Economics Research Unit, University of Aberdeen, Aberdeen, UK., Aceves-Martins M; Health Services Research Unit, University of Aberdeen, Aberdeen, UK., Quinton R; Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK., Gillies K; Health Services Research Unit, University of Aberdeen, Aberdeen, UK., Aucott LS; Health Services Research Unit, University of Aberdeen, Aberdeen, UK., Kennedy C; Health Economics Research Unit, University of Aberdeen, Aberdeen, UK., Manson P; Health Services Research Unit, University of Aberdeen, Aberdeen, UK., Oliver N; Faculty of Medicine, Imperial College London, London, UK., Wu F; Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, UK., Bhattacharya S; School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK., Dhillo WS; Faculty of Medicine, Imperial College London, London, UK., Jayasena CN; Faculty of Medicine, Imperial College London, London, UK., Brazzelli M; Health Services Research Unit, University of Aberdeen, Aberdeen, UK.
المصدر: Health technology assessment (Winchester, England) [Health Technol Assess] 2024 Aug; Vol. 28 (43), pp. 1-210.
نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Systematic Review
اللغة: English
بيانات الدورية: Publisher: NIHR Journals Library Country of Publication: England NLM ID: 9706284 Publication Model: Print Cited Medium: Internet ISSN: 2046-4924 (Electronic) Linking ISSN: 13665278 NLM ISO Abbreviation: Health Technol Assess Subsets: MEDLINE
أسماء مطبوعة: Publication: <2013-> : Southampton, UK : NIHR Journals Library
Original Publication: Winchester, UK : National Co-Ordinating Centre for HTA, c1997-
مواضيع طبية MeSH: Hormone Replacement Therapy*/adverse effects , Hormone Replacement Therapy*/methods , Hypogonadism*/drug therapy , Hypogonadism*/psychology , Testosterone*/administration & dosage , Testosterone*/adverse effects , Cost-Effectiveness Analysis*, Humans ; Male ; Cardiovascular Diseases/chemically induced ; Cardiovascular Diseases/epidemiology ; Quality of Life ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic
مستخلص: Background: Low levels of testosterone cause male hypogonadism, which is associated with sexual dysfunction, tiredness and reduced muscle strength and quality of life. Testosterone replacement therapy is commonly used for ameliorating symptoms of male hypogonadism, but there is uncertainty about the magnitude of its effects and its cardiovascular and cerebrovascular safety.
Aims of the Research: The primary aim was to evaluate the safety of testosterone replacement therapy. We also assessed the clinical and cost-effectiveness of testosterone replacement therapy for men with male hypogonadism, and the existing qualitative evidence on men's experience and acceptability of testosterone replacement therapy.
Design: Evidence synthesis and individual participant data meta-analysis of effectiveness and safety, qualitative evidence synthesis and model-based cost-utility analysis.
Data Sources: Major electronic databases were searched from 1992 to February 2021 and were restricted to English-language publications.
Methods: We conducted a systematic review with meta-analysis of individual participant data according to current methodological standards. Evidence was considered from placebo-controlled randomised controlled trials assessing the effects of any formulation of testosterone replacement therapy in men with male hypogonadism. Primary outcomes were mortality and cardiovascular and cerebrovascular events. Data were extracted by one reviewer and cross-checked by a second reviewer. The risk of bias was assessed using the Cochrane Risk of Bias tool. We performed one-stage meta-analyses using the acquired individual participant data and two-stage meta-analyses to integrate the individual participant data with data extracted from eligible studies that did not provide individual participant data. A decision-analytic Markov model was developed to evaluate the cost per quality-adjusted life-years of the use of testosterone replacement therapy in cohorts of patients of different starting ages.
Results: We identified 35 trials (5601 randomised participants). Of these, 17 trials (3431 participants) provided individual participant data. There were too few deaths to assess mortality. There was no difference between the testosterone replacement therapy group (120/1601, 7.5%) and placebo group (110/1519, 7.2%) in the incidence of cardiovascular and/or cerebrovascular events (13 studies, odds ratio 1.07, 95% confidence interval 0.81 to 1.42; p  = 0.62). Testosterone replacement therapy improved quality of life and sexual function in almost all patient subgroups. In the testosterone replacement therapy group, serum testosterone was higher while serum cholesterol, triglycerides, haemoglobin and haematocrit were all lower. We identified several themes from five qualitative studies showing how symptoms of low testosterone affect men's lives and their experience of treatment. The cost-effectiveness of testosterone replacement therapy was dependent on whether uncertain effects on all-cause mortality were included in the model, and on the approach used to estimate the health state utility increment associated with testosterone replacement therapy, which might have been driven by improvements in symptoms such as sexual dysfunction and low mood.
Limitations: A meaningful evaluation of mortality was hampered by the limited number of defined events. Definition and reporting of cardiovascular and cerebrovascular events and methods for testosterone measurement varied across trials.
Conclusions: Our findings do not support a relationship between testosterone replacement therapy and cardiovascular/cerebrovascular events in the short-to-medium term. Testosterone replacement therapy improves sexual function and quality of life without adverse effects on blood pressure, serum lipids or glycaemic markers.
Future Work: Rigorous long-term evidence assessing the safety of testosterone replacement therapy and subgroups most benefiting from treatment is needed.
Study Registration: The study is registered as PROSPERO CRD42018111005.
Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 17/68/01) and is published in full in Health Technology Assessment ; Vol. 28, No. 43. See the NIHR Funding and Awards website for further award information.
References: Andrologia. 2009 Oct;41(5):297-304. (PMID: 19737277)
J Sex Med. 2010 Jul;7(7):2572-82. (PMID: 20524974)
J Clin Endocrinol Metab. 2003 Jun;88(6):2673-81. (PMID: 12788872)
Int J Androl. 2006 Jun;29(3):381-91. (PMID: 16390499)
J Sex Res. 2017 May -Jun;54(4-5):486-506. (PMID: 28059572)
JAMA. 2006 Nov 15;296(19):2351-61. (PMID: 17105798)
PLoS One. 2018 Jun 27;13(6):e0199775. (PMID: 29949627)
JAMA. 2015 Aug 11;314(6):570-81. (PMID: 26262795)
Int J Endocrinol. 2013;2013:570413. (PMID: 23533404)
JAMA. 2017 Feb 21;317(7):708-716. (PMID: 28241355)
Diabetes Care. 2016 Jan;39(1):82-91. (PMID: 26622051)
J Clin Endocrinol Metab. 2015 Aug;100(8):2956-62. (PMID: 26158605)
Eur Urol. 2017 Dec;72(6):1000-1011. (PMID: 28434676)
Aging Male. 2008 Sep;11(3):140-5. (PMID: 18821290)
J Urol. 1997 Mar;157(3):849-54. (PMID: 9072584)
Clin Endocrinol (Oxf). 2016 Sep;85(3):436-43. (PMID: 27124404)
Ann Intern Med. 2020 Jan 21;172(2):105-118. (PMID: 31905375)
J Sex Med. 2017 Dec;14(12):1504-1523. (PMID: 29198507)
J Sex Med. 2017 Sep;14(9):1104-1115. (PMID: 28781213)
PLoS One. 2016 Sep 21;11(9):e0162480. (PMID: 27655114)
Int J Impot Res. 2007 Jul-Aug;19(4):411-7. (PMID: 17538639)
N Engl J Med. 2010 Jul 8;363(2):123-35. (PMID: 20554979)
Stroke. 2001 Sep;32(9):2131-6. (PMID: 11546907)
J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034. (PMID: 29495982)
Expert Opin Drug Saf. 2014 Oct;13(10):1327-51. (PMID: 25139126)
J Clin Endocrinol Metab. 2013 May;98(5):1891-900. (PMID: 23533227)
Andrology. 2016 Jan;4(1):33-40. (PMID: 26588809)
Int J Clin Pract. 2015 Apr;69(4):454-65. (PMID: 25382263)
Clin Endocrinol (Oxf). 2000 Dec;53(6):703-11. (PMID: 11155092)
Aging Male. 2018 Sep;21(3):158-169. (PMID: 29708829)
BMJ. 2013 Jan 28;346:f167. (PMID: 23358487)
Am J Alzheimers Dis Other Demen. 2015 Jun;30(4):421-30. (PMID: 25392187)
BJU Int. 2019 Mar;123(3):519-529. (PMID: 30216622)
BMJ Open. 2021 Jun 24;11(6):e045568. (PMID: 34168025)
Eur J Cancer Care (Engl). 2015 Sep;24(5):618-34. (PMID: 25630851)
JAMA. 2008 Jan 2;299(1):39-52. (PMID: 18167405)
Rejuvenation Res. 2017 Feb;20(1):9-14. (PMID: 27124096)
Med J Aust. 2012 Jun 4;196(10):642-5. (PMID: 22676880)
Health Qual Life Outcomes. 2003 May 01;1:15. (PMID: 12747807)
J Sex Med. 2016 Nov;13(11):1729-1736. (PMID: 27717790)
J Clin Endocrinol Metab. 2017 Apr 1;102(4):1161-1173. (PMID: 28324103)
Diabetes Care. 2011 Apr;34(4):828-37. (PMID: 21386088)
BMC Med. 2014 Nov 27;12:211. (PMID: 25428524)
Ann Intern Med. 2003 Aug 5;139(3):161-8. (PMID: 12899583)
Clin Psychol Rev. 2016 Nov;49:106-118. (PMID: 27664823)
Transl Androl Urol. 2017 Feb;6(1):60-68. (PMID: 28217451)
BMJ Open. 2016 Aug 05;6(8):e011805. (PMID: 27496237)
J Sex Med. 2019 Jun;16(6):812-820. (PMID: 31080101)
J Urol. 1994 Jan;151(1):54-61. (PMID: 8254833)
J Urol. 2015 Sep;194(3):759-60. (PMID: 26292880)
Eur Heart J Qual Care Clin Outcomes. 2022 Mar 2;8(2):187-194. (PMID: 33346822)
J Ment Health Policy Econ. 2016 Jun;19(2):79-89. (PMID: 27453455)
J Adv Nurs. 2004 Sep;47(5):467-74. (PMID: 15312109)
Health Qual Life Outcomes. 2003 Oct 06;1:51. (PMID: 14613571)
J Sex Med. 2012 Oct;9(10):2724-32. (PMID: 22989267)
Clin Endocrinol (Oxf). 2013 Oct;79(4):564-70. (PMID: 23480258)
Urology. 2004 Apr;63(4):641-6. (PMID: 15072869)
BMC Med Res Methodol. 2008 Jul 10;8:45. (PMID: 18616818)
Value Health. 2010 Aug;13(5):509-18. (PMID: 20230546)
Am J Physiol Endocrinol Metab. 2014 Feb 15;306(4):E433-42. (PMID: 24326421)
J Urol. 2016 Mar;195(3):699-705. (PMID: 26498057)
Aging Male. 2009 Jun-Sep;12(2-3):77-85. (PMID: 19811219)
J Sex Med. 2011 Jul;8(7):2079-89. (PMID: 21492400)
Trials. 2014 Feb 05;15:49. (PMID: 24495582)
Int J Impot Res. 2008 Jul-Aug;20(4):378-87. (PMID: 18480825)
J Sex Med. 2014 Jan;11(1):262-72. (PMID: 23937088)
Health Technol Assess. 2021 Apr;25(25):1-166. (PMID: 33861194)
PLoS Med. 2015 Oct 27;12(10):e1001895. (PMID: 26506244)
J Clin Endocrinol Metab. 2014 Oct;99(10):3821-8. (PMID: 24978674)
J Am Geriatr Soc. 2010 Jun;58(6):1134-43. (PMID: 20722847)
Scand J Clin Lab Invest. 2008;68(7):641-8. (PMID: 19378437)
N Engl J Med. 2010 Jul 8;363(2):109-22. (PMID: 20592293)
Exp Ther Med. 2016 Mar;11(3):853-863. (PMID: 26998003)
J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744. (PMID: 29562364)
Med J Aust. 2016 Sep 5;205(5):228-31. (PMID: 27581270)
Int J Androl. 1999 Aug;22(4):261-5. (PMID: 10442299)
Aging Male. 2012 Dec;15(4):198-207. (PMID: 22834649)
J Endocrinol Invest. 2010 Dec;33(11):776-83. (PMID: 20220293)
Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):532-40. (PMID: 22740013)
BJGP Open. 2021 Apr 26;5(2):. (PMID: 33293408)
Am J Med. 2017 Mar;130(3):293-305. (PMID: 27751897)
J Clin Endocrinol Metab. 2010 Jun;95(6):2536-59. (PMID: 20525905)
J Sex Med. 2010 Oct;7(10):3495-503. (PMID: 20646185)
Metabolism. 2000 Sep;49(9):1239-42. (PMID: 11016912)
J Sex Med. 2013 Jun;10(6):1612-27. (PMID: 23551886)
Eur Heart J Qual Care Clin Outcomes. 2016 Jan 20;2(2):125-140. (PMID: 27042338)
Aging Male. 2002 Jun;5(2):74-86. (PMID: 12198738)
J Clin Endocrinol Metab. 2010 Oct;95(10):4743-7. (PMID: 20660052)
Clin Nurse Spec. 2010 Jul-Aug;24(4):191-3. (PMID: 20526118)
Stat Med. 2020 Jul 10;39(15):2115-2137. (PMID: 32350891)
Evid Based Ment Health. 2018 May;21(2):72-76. (PMID: 29650528)
J Clin Endocrinol Metab. 2010 Feb;95(2):639-50. (PMID: 20061435)
Aging Male. 2009 Dec;12(4):104-12. (PMID: 19883295)
Andrology. 2020 Sep;8(5):970-987. (PMID: 32026626)
BJU Int. 2012 Jul;110(2):260-5. (PMID: 22093057)
Lancet Diabetes Endocrinol. 2021 Jan;9(1):32-45. (PMID: 33338415)
Aging Male. 2016 Jun;19(2):90-5. (PMID: 26927629)
Eur J Endocrinol. 2013 Oct 21;169(6):725-33. (PMID: 23999642)
Patient Prefer Adherence. 2012;6:631-41. (PMID: 22969294)
Endocrinol Metab (Seoul). 2020 Sep;35(3):526-540. (PMID: 32981295)
N Engl J Med. 2016 Feb 18;374(7):611-24. (PMID: 26886521)
J Clin Endocrinol Metab. 2004 Feb;89(2):503-10. (PMID: 14764753)
Mayo Clin Proc. 2015 Aug;90(8):1104-15. (PMID: 26205546)
Patient. 2016 Apr;9(2):181-90. (PMID: 26334870)
Clin Endocrinol (Oxf). 2021 May;94(5):827-836. (PMID: 33420743)
J Sex Med. 2016 Nov;13(11):1737-1749. (PMID: 27692845)
Pharmacoeconomics. 2014 Oct;32(10):967-79. (PMID: 25027943)
J Sex Med. 2008 Dec;5(12):2842-52. (PMID: 19090941)
Value Health. 2013 Mar-Apr;16(2):e1-5. (PMID: 23538200)
J Clin Endocrinol Metab. 2010 Jun;95(6):2560-75. (PMID: 20525906)
BMC Med. 2013 Apr 18;11:108. (PMID: 23597181)
J Sex Med. 2006 Jul;3(4):706-715. (PMID: 16839327)
Diabetes Obes Metab. 2016 Oct;18(10):980-9. (PMID: 27265844)
Health Econ. 2012 Dec;21(12):1508-12. (PMID: 22250070)
BMJ. 2000 Apr 29;320(7243):1165-8. (PMID: 10784537)
فهرسة مساهمة: Keywords: CARDIOVASCULAR DISEASES; ECONOMIC EVALUATION; HYPOGONADISM; INDIVIDUAL PARTICIPANT DATA META-ANALYSIS; QUALITY OF LIFE; SEXUAL FUNCTION; TESTOSTERONE
Local Abstract: [plain-language-summary] Testosterone is a hormone which is vital for sexual activity, bone growth and muscle development in men. Men with low testosterone levels may experience problems with erections and may suffer from brittle bones (osteoporosis), weakness, feeling down (low mood) and tiredness. The manifestations of low testosterone can be treated with testosterone replacement therapy. However, there is current uncertainty about the positive effects of testosterone replacement therapy and its safety. We brought together results from all available medical studies that looked at the use of testosterone replacement therapy in men with low testosterone and contacted the doctors who led these studies to gather further information on their participants. We found 35 studies (5601 participants) conducted in different countries, 17 of which provided additional information on their participants. We did not find any evidence to show that testosterone replacement therapy increases the risk of heart problems, or any evidence to show that some men who take testosterone replacement therapy benefit more than others. Men with low testosterone reported having low mood, poor concentration and lack of energy; however, medical studies often failed to prove that these manifestations improved with testosterone replacement therapy. Most medical studies were conducted among white men in North America using questionnaires designed specifically for them; therefore, the results may not reflect the experiences of men in other countries and from more diverse ethnic backgrounds. There is too much uncertainty about the benefits of testosterone replacement therapy to accurately estimate its value for money for the NHS. We think our findings offer some reassurance to doctors and patients that testosterone replacement therapy does not increase the risk of heart problems. New studies are needed to find out whether some groups of men (such as older or younger men) are more likely to benefit from testosterone replacement therapy more than others. It is also important to develop tools which better reflect the experience of men from a diverse range of social and ethnic backgrounds. To inform men with low testosterone about our findings, we are creating a website with dedicated YouTube video clips.
المشرفين على المادة: 3XMK78S47O (Testosterone)
تواريخ الأحداث: Date Created: 20240909 Date Completed: 20240909 Latest Revision: 20240923
رمز التحديث: 20240924
مُعرف محوري في PubMed: PMC11404359
DOI: 10.3310/JRYT3981
PMID: 39248210
قاعدة البيانات: MEDLINE
الوصف
تدمد:2046-4924
DOI:10.3310/JRYT3981